Disagree
Home Livewell Pharmaceuticals Livewell Pharmaceuticals
Tirzepatide
Tirzepatide - Livewell Pharmaceuticals

Tirzepatide - Livewell Pharmaceuticals

Brand:
Category:
Substance:
Package:
5 mg
Price:
$130.00 - $130.00
See options
Product Overview
Approved in 2022, tirzepatide (Mounjaro®) is a dual GIP/GLP-1 receptor agonist designed for patients with Type 2 Diabetes. It delivers superior glycemic control and weight loss benefits compared to existing GLP-1 therapies. Clinical data from the SURPASS-4 study highlighted its reduced mortality rates versus insulin glargine during the pandemic. With its dual-action design and strong efficacy, tirzepatide is a leading candidate for future trials targeting obesity and other metabolic complications.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tirzepatide by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.

Products
Show more
FAQ
Does Tirzepatide help with weight loss?
Yes, it has demonstrated substantial weight reduction in clinical trials, making it valuable for patients with T2D and obesity.
Is it approved for obesity treatment alone?
Not yet, but its dual mechanism suggests strong potential for future obesity indications.
How does it compare to insulin?
In trials, it outperformed insulin glargine in reducing mortality and improving metabolic outcomes.